PULMA

Breath-based lung cancer pre-screening

Lung health,
one breath away.

Pulma is a portable breath-analysis device and companion app that pre‑screens for lung cancer risk from a 10‑second breath sample — no needles, no scans.

Explore the Solution See Our Impact
Patent Number 2603006842
The Pulma breath-analysis device
Pulma app showing a lung cancer risk gauge
10-second breath scan
Results in the app
10 secbreath sample per scan
VOCsbreath-pattern analysis
Bluetoothresults sent to the app
No needlesnon-invasive, no radiation

What is Pulma

Pulma is a handheld breath-analysis device paired with a mobile app. Breathe into the device for 10 seconds and its sensors read the pattern of volatile organic compounds (VOCs) in your breath. The reading is sent to the app over Bluetooth, which shows a lung cancer risk level and whether a visit to a doctor is recommended.

Learn More
The Pulma device
Pulma app home screen Pulma app scan results screen

Why it matters

Lung cancer is the most diagnosed cancer and the leading cause of cancer death worldwide, with about 2.5 million new cases and 1.8 million deaths in 2022. Survival is far higher when it is found early, yet early lung cancer rarely causes symptoms and screening still means a hospital visit and a CT scan. Pulma makes a first check quick, non-invasive and portable, so more people know when to see a doctor.

Learn More
Presenting the Pulma app to a physician
Walking a senior physician through Pulma

Our Recognition

Pulma is patented and has been presented to physicians at a hospital Oncology and Hematology Center, where our team demonstrated the device and app.

Learn More
Patent Number 2603006842

Pulma breath-analysis device for lung cancer pre-screening.

The Pulma team with a physician at the Oncology and Hematology Center